Drugs & Targets Zynlonta receives FDA accelerated approval for large B-cell lymphoma April 30, 2021Vol.47 No.17
Drugs & Targets Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy April 30, 2021Vol.47 No.17
Drugs & Targets Mobocertinib NDA receives FDA Priority Review as treatment for EGFR Exon20 insertion+ metastatic NSCLC April 30, 2021Vol.47 No.17
Drugs & Targets Onureg receives Positive CHMP Opinion as frontline oral maintenance therapy for adults with AML in first remission April 30, 2021Vol.47 No.17
Drugs & Targets CHMP recommends approval for selumetinib in the EU as first medicine for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas April 30, 2021Vol.47 No.17
Drugs & Targets European Commission approves GSK’s Jemperli, the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer April 30, 2021Vol.47 No.17
Drugs & Targets Inivata, Agendia sign agreement for commercialization of RaDaR MRD liquid biopsy assay in breast cancer April 30, 2021Vol.47 No.17
Drugs & Targets Jemperli receives FDA accelerated approval for endometrial cancer April 23, 2021Vol.47 No.16
Drugs & Targets Opdivo + chemo regimen gets FDA approval for metastatic gastric cancer, esophageal adenocarcinoma indications April 23, 2021Vol.47 No.16
Drugs & Targets Bemarituzumab receives Breakthrough Therapy designation from FDA April 23, 2021Vol.47 No.16
